Delphi advisor to Galena Biopharma, Inc. in the acquisition of the drug Abstral in the U.S. from Orexo AB

Galena Biopharma is a biopharmaceutical company developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. Abstral is the leading fast-acting fentanyl product in Europe with a turnover of 54 million USD in 2012. Abstral was approved in 2011 by the U.S. Drug Administration The Food and Drug Administration (FDA). In June 2012, Orexo AB announced that it had acquired the U.S. rights to the product of Prostrakan Group plc, as part of a restructuring of the global rights for Abstral.

Delphi’s team, which was responsible for the Swedish legal advice, was led by Olof Myhrman, partner of Delphi’s M&A group and Caroline Ygge, partner of Delphi’s intellectual property group. The team also consisted of Elisabeth Eklund, partner in Delphi’s EU and competition group, Mikael Knutsson, partner in Delphi’s tax group, Henry Almström (intellectual property), Caroline Ekström (tax) and Eva Folkow (labour).